P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes. (April 2023)

• Record Type: Journal Article
• Authors: Johnston, S.; Toi, M.; O'Shaughnessy, J.; Rastogi, P.; Campone, M.; Neven, P.; Huang, C.S.; Huober, J.; Jaliffe, G. Garnica; Cicin, I.; Tolaney, S.; Goetz, M.P.; Rugo, H.; Senkus, E.; Testa, L.; Del Mastro, L.; Shimizu, C.; Wei, R.; Shahir, A.; Munoz, M.; Antonio, B. San; Andre, V.; Harbeck, N.; Martín, M.
• Is Part Of: Breast. Volume 68(2023)
• Page Start: S22
• Page End: S23
• Publication Date: 2023-04
• Subjects: Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/S0960-9776(23)00136-4
• Languages: English
• ISSNs: 0960-9776